HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M700116-MCP200v1 7/2/315    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Glossary Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yi, X. Articles by Fan, S.-T. Search for Related Content PubMed PubMed Citation Articles by Yi, X. Articles by Fan, S.-T. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 7:315-325, 2008.
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence^*

Xin Yi^,,¶, John M. Luk^,¶,||, Nikki P. Lee, Jirun Peng, Xisheng Leng^,**, Xin-Yuan Guan, George K. Lau, Laura Beretta^¶¶ and Sheung-Tat Fan

From the Department of Surgery, Peking University People's Hospital, Beijing, China, Department of Surgery, Clinical Oncology, and Medicine, Jockey Club Clinical Research Center, University of Hong Kong, Pokfulam, Hong Kong, and ^¶¶ Fred Hutchinson Cancer Research Center, Seattle, Washington 98109

Hepatocellular carcinoma (HCC) is well known for poor prognosis and short survival because of high recurrence rate even after curative surgery. Today there is no available biomarker or biochemical test to indicate HCC recurrence, and this study aims to identify protein markers that can discriminate postoperative patients with early recurrence (ER), i.e. disease relapsed within the first year. In this study, 103 hepatitis B-related HCC patients were recruited, and 68 of them were used for ER-related biomarker discovery study. Proteomic expression patterns of matched tumor and adjacent non-tumor tissues from these patients plus 16 normal liver tissues were delineated by the two-dimensional gel electrophoresis differential profiling method. Significant protein spots were evaluated by hierarchical clustering analysis. SSP4612 that yielded the highest receiver operating characteristic (ROC) curve value for the ER subgroup of HCC was subsequently identified by tandem mass spectrometry, and the corresponding expression patterns were further confirmed by quantitative PCR, Western blot, and immunohistochemistry. Correlation analysis with clinicopathological data was also examined. Proteomic profiling analysis revealed overexpression of mortalin (gene HSPA9) in HCC when compared with the non-tumor and normal liver tissues (area under the curve (AUC) = 0.821). Furthermore, elevated mortalin level was also detected in the ER subgroup of HCC versus the recurrence-free state (where no cancer recurs for >1 year) (AUC = 0.833, sensitivity = 90.9%, specificity = 71.4%). Metastatic HCC cell lines also exhibited higher levels of mortalin and HSPA9 mRNA. Clinically, mortalin overexpression in HCC was closely associated with advanced tumor stages and venous infiltration, having implications for increased malignancy and aggressive behavior. Mortalin (HSPA9) is associated with HCC metastasis and thus suggested as a tumor marker for predicting early recurrence, which may have immediate clinical applications for cancer surveillance after curative surgery.

^** To whom correspondence may be addressed: E-mail: lengxisheng{at}pkuph.edu.cn

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?